



PROTOCOL AMENDMENT

An observational study of patient cohorts who previously received long-term treatment with pioglitazone or placebo in addition to existing anti diabetic medications.

Sponsor: Takeda Global R&D Centre (Europe) Ltd
Arundel Great Court, 2 Arundel Street
London, WC2R 3DA United Kingdom

Study Number: EC-445

IND Number: N/A **EudraCT Number:** N/A

Investigational Medicinal Product: AD-4833

Amendment Number: 2

Global Amendment ☒

Amendment applicable to all sites

Local Amendment ☐

**Countries Affected by
this Local Amendment:**

Amendment Date: 11 January 2007

CONFIDENTIAL PROPERTY OF TAKEDA

This document is a confidential communication of Takeda Global Research & Development Centre (Europe) Ltd, London, United Kingdom. Acceptance of this document constitutes the agreement by the recipient that no information contained herein will be published or disclosed without written authorization from Takeda Global R&D Centre (Europe) Ltd except to the extent necessary to obtain informed consent from those persons participating in the study. Furthermore the information is meant for review by the recipient, his/ her staff, and applicable institutional review committee.





CONFIDENTIAL

APPROVAL SIGNATURES

Representatives of Takeda Global R&D Centre (Europe) Ltd

I agree to conduct this trial in accordance with the requirements of this Clinical Trial Protocol and also in accordance with the following:

- World Health Organisation (WHO) Declaration of Helsinki (2000)
- Respective local laws and regulations

 Dr. Alfonso Perez, MD Vice-President, Clinical Science Takeda Global R&D Center Inc	11/12/07 Date	 Mr. Paul Worthington, MSc BSc C. Stat Senior Manager, Statistics Takeda Global R&D Centre (Europe)	15 th Jan 2007 Date
 Mr. Karl Redhead, BSc (Hons) RN MICR Senior Study Manager, Clinical Operations Takeda Global R&D Centre (Europe)	15-JAN-07 Date	 Dr. Anne-Ruth van Troostenburg de Bruyn tGP MFPM Dip. Pharm. Med. (RCP) Medical Director, Pharmacovigilance Takeda Global R&D Centre (Europe)	15 Jan 07 Date

CONFIDENTIAL

Investigator Agreement

I confirm that I have read and understand this protocol. I agree to conduct this trial in accordance with the requirements of this protocol, and also in accordance with the following:

- WHO Declaration of Helsinki (2000)
- Respective local laws and regulations

Signature of Investigator

Date

Investigator Name (print or type)

Investigator Title

Name of Facility

Location of Facility (City)

CONFIDENTIAL

DESCRIPTION OF PROTOCOL AMENDMENTS

Amendment 2 - Global Protocol Amendment

The purpose of amendment number 2 is:

Protocol EC-445 outlines an investigation into the effects of prolonged peroxisome proliferator-activated receptor (PPAR) agonist therapy on mortality, macrovascular morbidity and incidence of malignancy in high-risk patients with diabetes mellitus. In particular, as an observational follow-up study to the PROACTIVE study, EC-445 provides an important opportunity to address these important matters in a study population where there was a placebo-treated control group.

In line with the intention to minimize complexity of this observational follow up study, basic data were specified for collection in the original version of the study protocol. However, it is now considered that this study data would be enhanced by the collection of additional information on cases of reported malignancies and thiazolidinedione therapy.

CONFIDENTIAL

PROPOSED AMENDMENTS

Page 15, 16.2.4 Malignancy

Existing Text

Details (*site of primary malignancy, histological classification and date of diagnosis*) of any malignancies diagnosed since the last assessment will be recorded at each assessment.

Revised Text

Details (*site of primary malignancy, histological classification and date of diagnosis, **additional information for bladder cancer (as detailed in appendix 1) and additional information for other malignancies (as detailed in appendix 2)***) of any malignancies diagnosed since the last assessment will be recorded at each assessment.

This expanded list of details will be collected for all cases of malignancy which have been reported since study start.

Consideration may be given to the need for further information to be requested from the investigator, in the follow up of individual cases of reported malignancy.

Rationale for Amendment

This amendment will permit the collection of more comprehensive data for analysis of reported malignancies.

Page 15, 16.2.5 Anti-diabetic Medication and Concomitant Medication

Existing Text

Details of patient's current anti-diabetic, lipid, cardiovascular and anti-platelet medication will be recorded at each assessment (*drug class only*).

Revised Text

Details of patient's current anti-diabetic (**For thiazolidinediones, additional information will be collected as detailed in appendix 3**), lipid, cardiovascular and anti-platelet medication will be recorded at each assessment

Rationale for Amendment

This amendment will permit the collection of more comprehensive data for analysis of concomitant medication usage.

CONFIDENTIAL

Appendix 1 - Additional Information: Bladder Cancer

The following additional information will be collected for reported cases of bladder cancer:

- cancer staging
- smoking history
- exposure to industrial carcinogenic agents
- exposure to potentially carcinogenic drugs
- history of chronic irritation of bladder
- history of schistosomiasis (Bilharzia)
- family history of bladder cancer
- histological type of bladder cancer
- history of haematuria

CONFIDENTIAL

Appendix 2 - Additional Information: Malignancies

The following additional information will be collected for reported cases of malignancies:

- cancer staging
- smoking history
- alcohol history
- exposure to industrial carcinogenic agents
- exposure to potentially carcinogenic drugs
- history of the same or other malignancies
- history of chronic local inflammations
- family history of malignancy

CONFIDENTIAL

Appendix 3 - Additional Information: Thiazolidinedione use

The following additional information will be collected for all reported thiazolidinedione use:

- Drug Name
- Total Daily Dose
- Start and Stop Dates

CONFIDENTIAL